Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635889 | 0.80 | ALDH1A1 (0.53) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL22541549 | 0.77 | HCRTR2 (0.43) | HCRTR2FKBP1APOLB | |
| SCHEMBL22891895 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KMT2AHCRTR2MAPTPOLB | |
| SCHEMBL11757120 | 0.75 | ALDH1A1 (0.48) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL26258441 | 0.75 | KMT2A (0.48) | ALDH1A1GAAHPGDHSD17B10KMT2A | |
| SCHEMBL7107767 | 0.74 | ALDH1A1 (0.57) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL20203666 | 0.74 | ALDH1A1 (0.57) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL13873135 | 0.73 | ALDH1A1 (0.53) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL16254920 | 0.73 | HPGD (0.51) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL22047940 | 0.73 | ALDH1A1 (0.55) | EPHX2ALDH1A1SMN1; SMN2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | EPHX2 3903/4885ALDH1A1 4182/4885SMN1; SMN2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.